Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Apixaban Shows Mortality Advantage, But Will It Survive FDA Scrutiny?

Executive Summary

Bristol-Myers Squibb/Pfizer’s Eliquis (apixaban) may be the first of the new anticoagulants to show a significant mortality benefit in the atrial fibrillation population, but it remains to be seen whether this advantage will withstand FDA’s regulatory scrutiny.

Related Content

Eliquis Approval Delayed By Fraud In China, Dispensing Errors In Pivotal Trial
Eliquis Approval Delayed By Fraud, Dispensing Errors In Pivotal Trial
“Marginal” Mortality Benefit Belongs In Eliquis’ Label, But Not The Indication Statement, FDA Says
ROCKET AF’s Design Causes Headaches For Xarelto Sponsors
Xarelto Faces Approval, Labeling Obstacles Even After Cmte. Endorsement
Xarelto Atrial Fibrillation Data Suggest Lines Of Advisory Committee Inquiry
FDA Approval Of Xarelto Bodes Well For Drug’s Future Expansion
Bristol/Pfizer's Apixaban: Third To Market But Best-In-Class?
FDA Pradaxa Approval Balances Efficacy And Bleeding Risk
FDA Pradaxa Approval Balances Efficacy And Bleeding Risk





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts